This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NICE Confirms AGNSS Positive Assessment That Eculizumab (Soliris®) Is A Very Effective Treatment For AHUS Patients And Produces Substantial Quality-Adjusted Life Year Gains Of A Magnitude Rarely Seen For A New Drug

Alexion Pharmaceuticals (Nasdaq:ALXN) is pleased that the National Institute for Health and Clinical Excellence (NICE) Evaluation Committee has acknowledged that eculizumab (Soliris ®) is a very effective treatment option for patients with aHUS, and that the use of eculizumab would be of significant value to patients with this life-threatening disorder who have no other treatment options.

In an Evaluation Consultation Document (ECD) released today, the NICE Evaluation Committee confirmed that currently available supportive care for patients with aHUS has limited impact on disease morbidity and mortality, but a substantial negative effect on a patient’s quality of life. Importantly, the Committee underscored that substantial restoration of health for a very long period is achieved with ongoing treatment with eculizumab. The Committee also concluded that eculizumab produced a substantial gain in quality-adjusted life years (QALY, a measure of the number of high-quality years of life gained) of a magnitude rarely seen for a new drug treatment – let alone one for an ultra-rare disorder.

Today’s very positive assessment by NICE of the clinical value of eculizumab for patients with aHUS aligns with the two prior positive recommendations from Government – AGNSS and NHS England. In addition, NICE confirmed today that the broad interim NHS England commissioning policy for eculizumab treatment of existing and new patients with aHUS will continue.

However, Alexion is concerned that nearly 3 years after Government commenced its evaluation, and more than 1 year after eculizumab was referred to NICE, the Committee was still unable to provide a formal recommendation whether eculizumab should be nationally commissioned. Additionally, NICE has now stated that it will seek further information from NHS England on what considerations relating to the management of its specialised commissioning budget it considers should be taken into account. NICE has also asked the company to provide additional information related to budget impact. NICE has not requested any additional clinical effectiveness information from Alexion.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,011.94 -28.43 -0.16%
S&P 500 2,109.60 -2.13 -0.10%
NASDAQ 5,076.5240 -6.4050 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs